MedDataX Logo

FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey

NCT00683891 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2008-06-19

No results posted yet for this study

Summary

AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or other atypical antipsychotics treatments. Another important clinical observation reported by doctors is a considerable reduction in hypersalivation when FazaClo administration is compared to other antipsychotic treatments. Based on the findings described above, and on the real need for effective and safer treatments for schizophrenia, AZUR Pharma has decided to design and conduct an observational study in a large number of patients taking FazaClo to prove the received clinical reports from physicians. Better understanding and evaluation of these beneficial findings are necessary to provide physicians information for improved treatment decision.

Conditions

  • Weight Gain
  • Sialorrhea

Interventions

DRUG

FazaClo (clozapine, USP) ODT

Sponsors & Collaborators

  • Azur Pharma, Inc

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683891 on ClinicalTrials.gov